|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For BC, BRCA carriers showed a more advanced histological stage, higher risk of bilateral neoplasms (OR = 4.3; 95% CI = 1.3-11.4, for BRCA2 carriers) and worse OS rate at 5-, 10- and 15- years, than women with sporadic tumors.
|
31771539 |
2019 |
|
Sporadic Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Survival analyses revealed that BRCA1 expression was associated with the decreased disease-free survival (DFS) rate of patients with FBC (versus no BRCA1 expression) and that FANCD2 was associated with decreased DFS of patients with SBC (versus no FANCD expression).
|
30881493 |
2019 |
|
Sporadic Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is well known that BRCA1 and BRCA2 play a central role in DNA repair, but the relationship between BRCA1 and BRCA2 mRNA expression and response to neoadjuvant chemotherapy in sporadic breast cancer patients has not been well established.
|
29047188 |
2018 |
|
Sporadic Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to evaluate the level of expression of the BRCA1 and BRCA2 proteins in sporadic breast cancer cases to determine the functional role of these genes in breast carcinogenesis.
|
25879355 |
2016 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whereas the cumulative 10-year incidence of second primary breast cancer is high in BRCA1 mutation carriers, the estimates in BRCA2 mutation carriers and women with variants of unknown clinical significance are similar to those reported in women with sporadic breast cancer.
|
25975955 |
2015 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel BRCA2 in frame deletion in a Tunisian woman with early onset sporadic breast cancer.
|
26320393 |
2015 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MD was associated with subsequent development BC (OR per category of MD=1.45; 95 % confidence interval=1.18-1.78, P-value<0.001), with no significant differences between BRCA1 and BRCA2 mutation carriers (P-value=0.48).
|
26163143 |
2015 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early-onset diagnosis is an eligibility criterion for BRCA1 and BRCA2 (BRCA) testing in sporadic breast cancer patients.
|
25342642 |
2014 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings uncover a BRCA2 regulatory and signaling pathway in sporadic breast cancer and support a functionally and clinically relevant epigenetic mechanism in cancer pathogenesis.
|
22158906 |
2012 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.
|
21918853 |
2012 |
|
Sporadic Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of this study was to evaluate the contribution of the BRCA1 and BRCA2 promoter methylation in the pathogenesis of sporadic breast cancer in Tunisian patients.
|
21978880 |
2012 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we explore the relationships between the MSA and the Rad51 gene, which encodes a DNA repair enzyme that interacts with BRCA1 and BRCA2, in BRCA1 mutation carriers and women with sporadic breast cancer.
|
21708019 |
2011 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, EMSY amplification occurred at a lower frequency in BRCA2 mutation carriers providing evidence to support EMSY amplification as a somatic surrogate for BRCA2 loss in sporadic breast cancer.
|
19636701 |
2010 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, strategies to target the underlying genetic defects in BRCA1- and BRCA2-associated breast and ovarian cancers are emerging and may have implications for certain types of sporadic breast cancer.
|
20816575 |
2010 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA2-associated breast cancer is more sensitive to standard first-line chemotherapy for metastatic breast cancer in comparison with sporadic breast cancer, especially to anthracyclines.
|
19564533 |
2009 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the current study was to investigate the frequency of these BRCA1 and BRCA2 mutations in southern Iranian familial and sporadic cases with breast cancer.Two hundred fifty women with sporadic breast cancer, 55 women with a familial history of breast cancer in their first degree-relatives and 200 healthy women formed the studied groups.
|
19877752 |
2009 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The studies we have performed during the last few years in familial breast tumours (BRCA1, BRCA2 and non-BRCA1/2) widen questions about the development of sporadic breast cancer to hereditary breast cancer.
|
18596026 |
2008 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hereditary breast cancer arising in carriers of mutations in the BRCA1 and BRCA2 genes differs from sporadic breast cancer and from non-BRCA1/2 familial breast carcinomas.
|
18544963 |
2008 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using breast cancer tumour microarrays, immunohistochemical expression of cytokeratin (CK)-5/6, CK-14 and CK-17 was evaluated in breast tumours from BRCA1 families (n = 46), BRCA2 families (n = 40), non-BRCA1/BRCA2 families (n = 358) and familial breast cancer patients with one first-degree relative affected by breast or ovarian cancer (n = 270), as well as from patients with sporadic breast cancer (n = 364).
|
18275599 |
2008 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine if there is any difference in PML protein expression in breast cancer of BRCA1 and BRCA2 gene mutation carriers compared to sporadic breast cancer and if the PML protein can be used as a prognostic marker.
|
17822314 |
2007 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism.
|
17945002 |
2007 |
|
Sporadic Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, this study reports for the first time CAV1 expression in BRCA1 and BRCA2 hereditary breast cancer and identifies CAV1 as a marker associated with a basal-like-phenotype in both hereditary and sporadic breast cancer.
|
16541313 |
2006 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
|
17100994 |
2006 |
|
Sporadic Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BRCAx-related tumors were characterized by more frequent LOH at 22q relative to sporadic breast cancer (P < 0.02), and differed significantly from BRCA1- and BRCA2-related tumors in their positivity for Bcl2.
|
16551851 |
2006 |
|
Sporadic Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer.
|
17145824 |
2006 |